<studyguide xsi:noNamespaceSchemaLocation="assets/IvimedsTutor2.xsd" folder="ManuelFaria" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><event id="11794097526401" title="Office Visit 1"><openquestion id="11794097526402" status=""><question><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">What new problems would you put on the problem list?</FONT></P></TEXTFORMAT>]]></p></xhtml></question><response><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Any of the following entries on the problem list would be acceptable:</FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">hypertension</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">leg pain on exercise (or, peripheral vascular disease)</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">benign prostatic hypertrophy (or enlarged prostate)</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">obesity</FONT></LI></TEXTFORMAT>]]></p></xhtml></response></openquestion><openquestion id="11794097526403" title="" status=""><question><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">What learning objectives do you have?</FONT></P></TEXTFORMAT>]]></p></xhtml></question><response><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Be sure that the following learning objectives are also included on your list.</FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">physiology of blood pressure control (see next page to learn more about the determinants of blood flow)</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">anatomy of the circulation of the leg </FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">pharmacology of diuretics (e.g, hydrochlorothiazide) and alpha-1 adrenergic receptor blockers (e.g., doxazosin)</FONT></LI></TEXTFORMAT>]]></p></xhtml></response></openquestion><data id="12108082197698331" title=""><content><xhtml><p><![CDATA[<img alt="" src="determinants_v4.swf" width="" height=""/>]]></p></xhtml></content></data><openquestion id="12109296673741" title="Effect of hypertension on arterial tree" status=""><question><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">The complications of hypertension are important not only because of their effects on the arterial tree itself, but because of damage to major organs, i.e. brain, eye, heart, blood vessels and kidneys.</FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">From your knowledge of the circulation and of the structure of arteries, can you suggest structural and functional changes that may result from prolonged hypertension?</FONT></P></TEXTFORMAT>]]></p></xhtml></question><response><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Click next button for answers</FONT></P></TEXTFORMAT>]]></p></xhtml></response></openquestion><data id="12109298868922" title=""><content><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">The larger (elastic) arteries show internal elastic lamina thickening, smooth muscle hypertrophy and fibrosis.</FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">These changes reduce the lumen, increase shear stress on the intima, increase turbulence, decrease endothelial function and reduce distensibility/compliance.</FONT></P></TEXTFORMAT><img alt="" src="hypertinsive_arteries.jpg" width="" height=""/><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">The smaller arteries show hyaline sclerosis which narrows the lumen. The histology slide shows hyaline arteriolar sclerosis, possibly the result of long-standing, uncontrolled hypertension. The vessel appears to be greater than 80% occluded.</FONT></P></TEXTFORMAT><img alt="" src="Hyaline_arteriolar_sclerosis.jpg" width="" height=""/>]]></p></xhtml></content></data><openquestion id="12109300164443" title="PVR" status=""><question><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">What effect do these structural changes found in arteries following hypertension have on peripheral vascular resistance (PVR)?</FONT></P></TEXTFORMAT>]]></p></xhtml></question><response><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">PVR increases. This in turn results in a further increase in blood pressure. Click next to see a graphical representation.</FONT></P></TEXTFORMAT>]]></p></xhtml></response></openquestion><data id="12109301724345" title="Further reading"><content><xhtml><p><![CDATA[<img alt="" src="pvr_chart.swf" width="" height=""/><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">To read further on &apos;The Structure of Small Arteries in Essential Hypertension&apos; (A M Heagerty) click here: <A HREF="http://www.mcmaster.ca/inabis98/mulvany/heagerty0861/two.html" TARGET="_blank"><B>http://www.mcmaster.ca/inabis98/mulvany/heagerty0861/two.html</B></A></FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">For explanatory text with images on the general structure of blood vessels and variations of vessel wall structure, click on the URL of the School of anatomy and Human Biology:  <A HREF="http://www.lab.anhb.uwa.edu.au/mb140/CorePages/Vascular/Vascular.htm#labmuscular" TARGET="_blank"><B><U>http://www.lab.anhb.uwa.edu.au/mb140/CorePages/Vascular/Vascular.htm#labmuscular</U></B></A></FONT></P></TEXTFORMAT>]]></p></xhtml></content></data><data id="12107242908702311" title=""><content><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"><B>Peripheral arterial occlusive disease</B></FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Hypertension is a major risk factor for peripheral arterial occlusive disease. Peripheral arterial occlusive disease (PAOD) results either from atherosclerotic or inflammatory processes causing lumen narrowing (stenosis), or from thrombus formation which is usually associated with underlying atherosclerotic disease. </FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">A digital subtraction angiogram of aorto-iliac arterial tree showing occlusion of the right common iliac artery from a patient with long-standing sustained hypertension.</FONT></P></TEXTFORMAT><img alt="" src="Peripheral arterial vascular disease.jpg" width="" height=""/>]]></p></xhtml></content></data><data id="12107256439442338" title=""><content><xhtml><p><![CDATA[<img alt="" src="Picture 1.png" width="" height=""/>]]></p></xhtml></content></data><data id="12107249563231122" title="Diuretics"><content><xhtml><p><![CDATA[<img alt="" src="Diuretics.png" width="" height=""/>]]></p></xhtml></content></data><data id="12107250592581173" title=""><content><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"><B>Beta-blockers</B></FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Beta-blockers have a role to play in the management of patients with hypertension. They are especially useful in hypertensive patients with concomitant coronary artery disease or congestive heart failure.</FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Beta-blockers decrease the hyperkinetic cardiac output and the high renin levels characteristic of young patients with hypertension.</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Beta-blockers reduce morbidity and mortality in patients with coronary disease or heart failure.</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Contraindications are bronchospasm and advanced heart block.</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Cold hands and feet are a common problem, as is fatigue.</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Examples of beta-blockers include: metoprolol, atenolol, and labetolol (labetolol also has some alpha-adrenoreceptor blocking activity).</FONT></P></TEXTFORMAT>]]></p></xhtml></content></data><data id="12107251744280924" title=""><content><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"><B>ACE-inhibitors</B></FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">ACE-inhibitors are widely prescribed in young white hypertensives.</FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">ACE-inhibitors are very effective in hypertensive patients with LV dysfunction, coronary artery disease, diabetes mellitus, or chronic renal disease/proteinuria.</FONT></P></TEXTFORMAT><img alt="" src="ACE-I.png" width="" height=""/>]]></p></xhtml></content></data><data id="12107253204706545" title=""><content><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"><B>Angiotensin II receptor blockers (ARBs)</B></FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Angiotensin II receptor blockers (ARBs) have similar effects to ACE-inhibitors. They are used as 2nd-line drugs (because of their high cost) in patients who do not tolerate ACE-inhibitors.</FONT></P></TEXTFORMAT><img alt="" src="ARBs.png" width="" height=""/>]]></p></xhtml></content></data><data id="12107253713867346" title=""><content><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"><B>Calcium channel blockers (CCBs)</B></FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">The calcium channel blockers (CCBs) are generally considered 2nd-line drugs.</FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">There are two main categories.</FONT></P></TEXTFORMAT><img alt="" src="CCBs.png" width="" height=""/>]]></p></xhtml></content></data><data id="121072543228766117" title=""><content><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"><B>Other agents</B></FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Other antihypertensive agents may be used in patients who are refractory to initial therapy.</FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Direct vasodilators have limited, but specific, uses. Hydralazine/isosorbide dinitrate is particularly useful in patients of African descent. Hydralazine can be used to lower blood pressure acutely in pregnancy, though nifedipine and labetolol are now the preferred first-line treatments.</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Minoxidil is best avoided in women because it causes hair growth and coarsens the features.</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Peripheral alpha-1 blockers such as doxazosin or terazosin may prove beneficial in those patients with hypertension who also have urinary tract outlet obstruction because they relax the outlet sphincter of the bladder.</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Central alpha-2 agonists such as clonidine and methyldopa are declining in use because of their prominent side-effect profile, especially dizziness, dry mouth, and sleepiness.</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Combined alpha-1 and beta-blockers such as labetolol are used intravenously in acute hypertension.</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Imidazoline-1 receptor agonists such as monoxidine, which modulate the central sympathetic nervous system outflow in the brain stem, are occasionally used.</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></P></TEXTFORMAT>]]></p></xhtml></content></data><openquestion id="11794097526404" status=""><question><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">After investigating your learning objectives, complete a management plan for Mr. Faria.</FONT></P></TEXTFORMAT>]]></p></xhtml></question><response><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Your management plan should have included the following:</FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">adding another antihypertensive drug to his regimen, preferably an alpha-1 adrenergic receptor blocker that might help his urinary symptoms as well</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">counseling patient on ways he can help to reduce blood pressure (losing weight, restricting salt intake, increasing daily exercise, eating low-fat diet)</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">recommending daily low-dose aspirin for prevention of heart attack and stroke</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">obtaining laboratory tests for other cardiovascular risk factors and evidence of end-organ damage and other etiologies of hypertension (hyperthyroidism)</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">see the patient back in 2-4 weeks to monitor response</FONT></LI></TEXTFORMAT>]]></p></xhtml></response></openquestion></event><event id="11794097526405" title="Office Visit 2"><openquestion id="11794097526406" status=""><question><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">What new problems would you put on the problem list?</FONT></P></TEXTFORMAT>]]></p></xhtml></question><response><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Any of the following entries on the problem list would be acceptable:</FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">hypokalemia</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">hypercholesterolemia</FONT></LI></TEXTFORMAT>]]></p></xhtml></response></openquestion><openquestion id="11794097526407" status=""><question><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">What learning objectives do you have?</FONT></P></TEXTFORMAT>]]></p></xhtml></question><response><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Be sure that the following learning objectives are also included on your list.</FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Side effects of antihypertensive drugs</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Physiology of adrenal cortex (aldosterone)</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Physiology of the adrenal medulla</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Pathology of adrenal medulla (pheochromocytoma)</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Pathology of adrenal cortex (adenoma, hyperplasia)</FONT></LI></TEXTFORMAT>]]></p></xhtml></response></openquestion><openquestion id="11794097526408" title="" status=""><question><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">After investigating your learning objectives, complete a management plan for Mr. Faria.</FONT></P></TEXTFORMAT>]]></p></xhtml></question><response><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Your management plan should have included the following:</FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Add another drug to control his high blood pressure (either a calcium-channel blocker, or ACE inhibitor; beta-blockers should probably be avoided because of their capacity to worsen peripheral arterial disease and his symptoms of intermittent claudication)</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Add a potassium supplement and instruct on including enough potassium in his diet and restricting salt</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Refer to a dietician for advise on reducing weight, lowering saturated fats, and restricting sodium</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Your management plan should not have included an extensive work-up for adrenal causes of his hypertension. Although his low potassium could be caused by an aldosterone-secreting adrenal adenoma, the far more likely scenario is that it is related to his diuretic and high sodium intake. If dietary interventions and potassium supplementation don?t normalize his potassium, then a work up for secondary causes would be justified.</FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Elevated cholesterol conveys an added risk for cardiovascular disease even in older persons. Lowering cholesterol has been shown to reduce risk in older men 65-75. While there are no hard-and-fast rules for treatment of someone over 75 as Mr. Faria is, most authorities would recommend lifestyle modification rather than drug therapy unless the patient had multiple risk factors and already showed evidence of subclinical atherosclerosis. Since Mr. Faria does have multiple risk factors and evidence of atherosclerosis, he would be a candidate for more aggressive treatment of his elevated cholesterol if he does not respond adequately to lifestyle changes.</FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">The evidence is quite strong that treating hypertension in patients 80 year of age or older is beneficial. (See Beckett NS, et al., Treatment of Hypertension in Patients 80 Years of Age or Older, N Engl J Med 2008; 358:1887-98.)</FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">See the next page for important considerations to keep in mind when confronted with difficult-to-treat hypertension.</FONT></P></TEXTFORMAT>]]></p></xhtml></response></openquestion><data id="12108094500088341" title=""><content><xhtml><p><![CDATA[<img alt="" src="Resistant HTN.jpg" width="" height=""/>]]></p></xhtml></content></data></event><event id="11794097526409" title="Office Visit 3"><openquestion id="117940975264010" status=""><question><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">What new problems would you put on the problem list?</FONT></P></TEXTFORMAT>]]></p></xhtml></question><response><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Any of the following entries on the problem list would be acceptable:</FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">	no new problems</FONT></LI></TEXTFORMAT>]]></p></xhtml></response></openquestion><openquestion id="117940975264011" status=""><question><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">What learning objectives do you have?</FONT></P></TEXTFORMAT>]]></p></xhtml></question><response><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Be sure that the following learning objectives are also included on your list.</FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Physiology of micturition</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Anatomy of the male reproductive system (prostate)</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Histology and pathology of the prostate gland</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Pharmacology of finasteride, alpha-adrenergic receptor blockers</FONT></LI></TEXTFORMAT>]]></p></xhtml></response></openquestion><openquestion id="117940975264012" status=""><question><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">After investigating your learning objectives, complete a management plan for Mr. Faria.</FONT></P></TEXTFORMAT>]]></p></xhtml></question><response><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Your management plan should have included the following:</FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Increase the dose of the alpha-1 adrenergic blocker (doxazosin) to 8 mg.</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Add a 5-alpha-reductase inhibitor (finasteride) to reduce prostate volume</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Increase the dose of the calcium-channel blocker (amlodipine) to 10 mg for better control of his systolic hypertension</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Refer to a urologist if symptoms do not improve in 6 months or if they worsen</FONT></LI></TEXTFORMAT>]]></p></xhtml></response></openquestion></event><event id="117940975264013" title="Office Visit 4"><openquestion id="117940975264014" status="" title=""><question><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">What new problems would you put on the problem list?</FONT></P></TEXTFORMAT>]]></p></xhtml></question><response><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Any of the following entries on the problem list would be acceptable:</FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">dizziness</FONT></LI></TEXTFORMAT>]]></p></xhtml></response></openquestion><openquestion id="117940975264015" status=""><question><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">What learning objectives do you have?</FONT></P></TEXTFORMAT>]]></p></xhtml></question><response><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Be sure that the following learning objectives are also included on your list.</FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Pharmacology of finasteride, alpha-adrenergic receptor blockers (follow up)</FONT></LI></TEXTFORMAT>]]></p></xhtml></response></openquestion><openquestion id="117940975264016" status="" title=""><question><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">After investigating your learning objectives, complete a management plan for Mr. Faria.</FONT></P></TEXTFORMAT>]]></p></xhtml></question><response><xhtml><p><![CDATA[<TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Your management plan should have included the following:</FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">maintain patient on current level of medications with counseling about getting up slowly and avoiding falls</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">praise patient for his success in dieting and encourage him to continue to lose weight and exercise and watch his salt and fat intake</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">refer to a urologist if symptoms worsen</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><LI><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">see again in 3-6 months</FONT></LI></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0"></FONT></P></TEXTFORMAT><TEXTFORMAT LEADING="2"><P ALIGN="LEFT"><FONT FACE="Arial Unicode MS,Arial,Helvetica" SIZE="12" COLOR="#0B333C" LETTERSPACING="0" KERNING="0">Click <A HREF="http://www.brown.edu/Research/Geriatrics/manuel_streaming.html" TARGET="_blank"><U>here</U></A> to listen to a case discussion of dizziness in the older patient by a geriatrician.</FONT></P></TEXTFORMAT>]]></p></xhtml></response></openquestion></event></studyguide>